The effect of different treatment strategies on glycolipid metabolism disorders and cardiovascular events in primary aldosteronism.

Hypertens Res

Department of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang, PR China.

Published: June 2024

AI Article Synopsis

  • A study examined the effects of spironolactone therapy versus surgical intervention on cardiovascular outcomes in patients with primary aldosteronism, analyzing data from 853 patients over several years.
  • Results showed that spironolactone treatment led to significantly better metabolic improvements, including reductions in BMI, blood pressure, and cholesterol levels, compared to surgery, which did not show notable changes pre- and post-operation.
  • The spironolactone group experienced fewer cardiovascular events and better overall metabolic health despite having higher hospitalization rates than those undergoing surgery, indicating its effectiveness for patients with primary aldosteronism.

Article Abstract

Recent studies have explored the association between primary aldosteronism and cardiovascular disease incidence. The association between specific primary aldosteronism treatments and differential improvement in cardiovascular event rates is yet to be established. This study was designed to compare the relative effects of spironolactone therapy and surgical intervention on cardiovascular outcomes among primary aldosteronism patients. This retrospective observational study included 853 primary aldosteronism patients from the First Affiliated Hospital of China Medical University between 2014 and 2022. Patients who had completed abdominal computed tomography (CT) examinations with similar metabolic characteristics and 6-month follow-up analyses were included in this study. These patients were separated into a surgical treatment group (n = 33) and a spironolactone treatment group (n = 51). Demographic data, biochemical analysis results, liver/spleen (L/S) X-ray attenuation ratio, hospitalization frequency, and cardiovascular events were compared between the two groups. The spironolactone group demonstrated significantly improved metabolic characteristics compared to the surgical group, shown by lower BMI, blood pressure, total cholesterol (TC), insulin resistance index (IRI), and reduced non-alcoholic fatty liver disease prevalence. Metabolic parameters did not differ significantly within the surgical treatment group when comparing pre- and postoperative values. The incidence of cardiovascular events was lower in the spironolactone group compared to the surgery group (23/33 vs. 20/51, P < 0.001) despite higher hospitalization rates(37/31 vs. 61/53, P < 0.001). In patients with primary aldosteronism, spironolactone treatment is more effective than surgical intervention in remediating abnormal lipid and glucose metabolism while improving cardiovascular outcomes. Chinese clinical trial registry registration number: ChiCTR2300074574.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41440-024-01648-0DOI Listing

Publication Analysis

Top Keywords

primary aldosteronism
20
cardiovascular events
12
treatment group
12
aldosteronism patients
8
metabolic characteristics
8
surgical treatment
8
spironolactone group
8
group
7
cardiovascular
6
primary
5

Similar Publications

Neonatal pseudo-hypoaldosteronism type 1 with a novel gene variant.

Sudan J Paediatr

January 2024

Department of Paediatrics, South West Acute Hospital, Enniskillen, UK.

Pseudohypoaldosteronism (PHA) is a rare disorder that mimics congenital adrenal hyperplasia (CAH). Renal type A1A of the disorder has a known gene mutation (NR3C2) and parents may be asymptomatic despite biochemical abnormalities. Meticulous interpretation of hormonal and biochemical data, and early liaison with endocrinology and renal teams are key in diagnosis.

View Article and Find Full Text PDF

Objectives: This study aimed to compare the clinical efficacy of dual-time Ga-pentixafor PET/CT with adrenal vein sampling (AVS) in PA lateralization.

Methods And Methods: We retrospectively analysed 161 patients with PA. We assessed the diagnostic performance of dual-time Ga-pentixafor PET/CT in diagnosing unilateral primary aldosteronism (UPA) and aldosterone-producing adenoma (APA).

View Article and Find Full Text PDF

Non-Hypertensive Effects of Aldosterone.

Int J Mol Sci

January 2025

Department of Hypertension and Diabetology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.

Aldosterone, the primary adrenal mineralocorticoid hormone, as an integral part of the renin-angiotensin-aldosterone system (RAAS), is crucial in blood pressure regulation and maintaining sodium and potassium levels. It interacts with the mineralocorticoid receptor (MR) expressed in the kidney and promotes sodium and water reabsorption, thereby increasing blood pressure. However, MRs are additionally expressed in other cells, such as cardiomyocytes, the endothelium, neurons, or brown adipose tissue cells.

View Article and Find Full Text PDF

Two billion people worldwide suffer from anemia, which can lead to the onset of cardiac disorders; nevertheless, the precise mechanisms remain unclear. There are at least three distinct mechanisms by which iron deficiency (ID) contributes to the development of cardiac disorders. First, ID increases concentrations of intact fibroblast growth factor-23 (iFGF-23), which promotes left ventricular hypertrophy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!